BETA vs PAR: Stock Comparison

Beta Drugs Ltd vs Par Drugs And Chemicals Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Beta Drugs Ltd is the larger company by market capitalisation. Beta Drugs Ltd shows a higher ROE, faster revenue growth and a higher ROCE, while Par Drugs And Chemicals Limited shows a lower P/E, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Beta Drugs Ltd and Par Drugs And Chemicals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BETA is more favourable on 8 of 13 scored metrics and PAR on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BETA is the larger company
₹2,558 Cr vs ₹116 Cr
P/E Ratio
PAR has a lower P/E
8.55x vs 57.18x
P/B Ratio
PAR has a lower P/B
0x vs 9.69x
EPS
BETA has higher earnings per share
₹40.9 vs ₹10.65
Revenue Growth (TTM YoY)
BETA has faster revenue growth
0% vs -12.2%
EPS Growth (TTM YoY)
BETA has faster EPS growth
0% vs -48.5%
Qtr Sales Growth
BETA has stronger quarterly sales growth
0.21% vs -12.2%
Qtr Profit Growth
BETA has stronger quarterly profit growth
-15.2% vs -48.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBETAPAR
SectorHealthcare
IndustryPharmaceuticals

Price

MetricBETAPAR
Live Price₹2,315.6₹93.79
Day Change1.69%-2.48%
Volume19,16412,063
52-Week High₹2,674₹114
52-Week Low₹990.1₹78.05
Distance from 52W High-13.4%-17.73%

Valuation

MetricBETAPAR
Market Cap₹2,558 Cr₹116 Cr
P/E Ratio57.18x8.55x
P/B Ratio9.69x0x
EPS₹40.9₹10.65
Book Value₹241₹90.52
Dividend Yield0%0%

Growth

MetricBETAPAR
Revenue Growth (TTM YoY)0%-12.2%
EPS Growth (TTM YoY)0%-48.5%
Qtr Sales Growth0.21%-12.2%
Qtr Profit Growth-15.2%-48.5%

Profitability & Leverage

MetricBETAPAR
ROE18.8%12.4%
ROCE19.2%16.5%
Net Margin10.78%12.65%
Operating Margin19.7%16.5%
Debt to Equity0.6x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBETAPAR
Promoter Holding59.1% 5.53 pp73.41%
FII Holding1.02% 0.14 pp0%
DII Holding6.23% 4.08 pp0.09% 0.09 pp
Public Holding33.65% 1.59 pp26.51% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Beta Drugs Ltd and Par Drugs And Chemicals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.